Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam pharmacokinetics during continuous renal replacement therapy in critically ill adults
2023-505536-35-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- May 2025
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of ceftazidime and avibactam in bacterial disease, sponsored by UZ Leuven. Primary endpoints: Pharmacokinetic parameters of ceftazidime and avibactam, PK/PD target attainment of ceftazidime and avibactam and 2 more. Planned start May 2025; status: authorised.
02
Drugs
ceftazidimeavibactam
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2023-505536-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505536-35-00.